Pioneering the way in Shingles therapy, Wintermute Biomedical initiates a Phase Ib clinical trial, backed by a successful $1.3M USD investment.

Breaking Ground in Shingles Treatment: Wintermute Biomedical Advances to Clinical Trials

Wintermute secures grant to partner with renowned Mycobacterium expert Professor Eric Nuermberger in pursuit of a breakthrough treatment for neglected Buruli ulcers.

Bridging innovation and opportunity: Wintermute Biomedical's spotlight at the BLUE KNIGHT™️ QuickPitch event

Wintermute's clinical advisory board gains the expertise of a renowned infectious disease expert, enhancing their efforts to combat shingles with their groundbreaking topical therapy Solexan™.

Wintermute joins forces with Dr. Fabian Kong at the University of Melbourne to combat the rise of multi-drug resistant oral gonorrhoea infections.

Wintermute Biomedical collaborates with Ten Carbon Chemistry to explore the potential of GS-2 in reusable food packaging with a $260,000 grant from the US Department of Agriculture.

Collaboration with Defence Science and Technology Group, Australia could be the start of a commercial venture for this antimicrobial biotech company.

Bringing innovative antimicrobial fatty acid formulations to agriculture and environmental industries.

Wintermute Biomedical's fatty acid formulation, GS-1, demonstrates anticancer activity. These findings were recently published in the International Journal of Molecular Sciences.

Our leading topical therapeutic passes first hurdle in shingles clinical pathway

GS-13 is our fatty acid formulation in development as a solution to systemic and antibiotic-resistant infections.

Testing of Wintermute’s topical antimicrobial therapy, Solexan™, at the State University of New York shows it has potent activity against Varicella Zoster Virus.

Novel inhalation therapy moves to animal trials in US $3 Billion fast-track COVID-19 treatments program under Dr Anthony Fauci.